A systematic methodology review of phase I radiation dose escalation trials-Reference-Cited by-同舟云学术

A systematic methodology review of phase I radiation dose escalation trials

Published:2010-05 Issue:2 Volume:95 Page:135-141
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Pijls-Johannesma Madelon,van Mastrigt Ghislaine,Hahn Steve M.,De Ruysscher Dirk,Baumert Brigitta G.,Lammering Guido,Buijsen Jeroen,Bentzen Soren M.,Lievens Yolande,Kramar Andrew,Lambin Philippe

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference84 articles.

1. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur J Cancer Clin Oncol 1985;21:1005–7.

2. Evaluation of early and late toxicities in chemoradiation trials;Bentzen;J Clin Oncol,2007

3. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy;Belderbos;Radiother Oncol J Eur Soc Ther Radiol Oncol,2003

4. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer;Blackstock;J Thorac Oncol,2006

5. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma;Bradley;Int J Radiat Oncol Biol Phys,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study;BMC Medicine;2023-07-05

2. Strahlentherapie mit Ionenstrahlen: rechtfertigen die klinischen Ergebnisse die hohen Kosten?;Die Onkologie;2022-09-19

3. A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations;Clinical Cancer Research;2022-05-12

4. Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT);Acta Oncologica;2022-03-14

5. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib;BMC Cancer;2019-09-10